AKT1 and melanoma: We propose that interfering with WNT5A signaling will affects PI3K-AKT and the β-catenin-MITF-EGFR axis, which would make Box-5 therapy useful for not only BRAFi-resistant melanomas but also melanomas that do not carry BRAF mutations.